BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study
详细信息 查看全文
- 作者：Philipp Hartera ; p.harter@gmx.de" class="auth_mail" title="E-mail the corresponding author ; Toby Johnsonb ; Dominique Berton-Rigaudc ; Sang-Yoon Parkd ; Michael Friedlandere ; Josep M. del Campof ; Muneaki Shimadag ; Fré ; dé ; ric Forgeth ; Mansoor R. Mirzai ; Nicoletta Colomboj ; Claudio Zamagnik ; John K. Chanl ; Martin Imhofm ; Thomas J. Herzogn ; Dearbhaile O'Donnello ; Florian Heitza ; Karen Kingp ; 1 ; Sandy Stinnettp ; 1 ; Catherine Barrettq ; 1 ; Minesh Jobanputrar ; 1 ; Chun-Fang Xub ; Andreas du Boisa
- 关键词：GWAS ; Ovarian cancer ; Progression-free survival ; Germline BRCA mutation ; Pazopanib
- 刊名：Gynecologic Oncology
- 出版年：2016
- 出版时间：March 2016
- 年：2016
- 卷：140
- 期：3
- 页码：443-449
- 全文大小：726 K
文摘
- •
To identify genetic markers associated with prognosis in ovarian cancer.
- •
Longer progression-free survival was observed in patients with BRCA1/2 mutations.
- •
Genetic counseling plays an important role and should be offered to all patients.